Submission Type
Poster
Start Date
April 2020
Abstract
Vulvar cancer is rare, mostly afflicting women aged 60 and older. The cancer is often preceded by a common vulvar rash, Lichen sclerosis, that is usually treated with the ultra-potent corticosteroid, clobetasol propionate. This treatment may, in turn, be associated with vulvar carcinogenesis. Quiescence, a common characteristic of stem cells, is a reversible state of growth arrest. Our results suggest that clobetasol is causing UMSCV-4 vulvar carcinoma cells to enter quiescence, and may allow them to evade the standard treatments that target rapidly proliferating populations. Furthermore, when these cells are removed from clobetasol and re-exposed, they proliferate at higher levels. This suggests that the initial clobetasol treatment selects for cells that are now unable to enter quiescence when re-exposed to clobetasol.
Recommended Citation
Jaramillo, Nolberto Jr. and Mustico, Nina, "365— Clobetasol-induced Quiescence in the Vulvar Carcinoma Cell Line UMSCV-4 Can Be Overcome by Repeated Removal and Re-exposure to this Ultrapotent Corticosteroid" (2020). GREAT Day Posters. 6.
https://knightscholar.geneseo.edu/great-day-symposium/great-day-2020/posters-2020/6
Included in
365— Clobetasol-induced Quiescence in the Vulvar Carcinoma Cell Line UMSCV-4 Can Be Overcome by Repeated Removal and Re-exposure to this Ultrapotent Corticosteroid
Vulvar cancer is rare, mostly afflicting women aged 60 and older. The cancer is often preceded by a common vulvar rash, Lichen sclerosis, that is usually treated with the ultra-potent corticosteroid, clobetasol propionate. This treatment may, in turn, be associated with vulvar carcinogenesis. Quiescence, a common characteristic of stem cells, is a reversible state of growth arrest. Our results suggest that clobetasol is causing UMSCV-4 vulvar carcinoma cells to enter quiescence, and may allow them to evade the standard treatments that target rapidly proliferating populations. Furthermore, when these cells are removed from clobetasol and re-exposed, they proliferate at higher levels. This suggests that the initial clobetasol treatment selects for cells that are now unable to enter quiescence when re-exposed to clobetasol.
Comments
Faculty Sponsor: Jani Lewis, Biology
Selected for presentation at American Association for Cancer Research Annual Meeting, San Diego, CA.